10406640

Source:http://linkedlifedata.com/resource/pubmed/id/10406640

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0205177, umls-concept:C0205531, umls-concept:C0226896, umls-concept:C0442027, umls-concept:C0762662, umls-concept:C0766718, umls-concept:C0876768, umls-concept:C1527415, umls-concept:C1880355
pubmed:issue	13
pubmed:dateCreated	1999-10-14
pubmed:abstractText	The development of a COX-2 inhibitor rofecoxib (MK 966, Vioxx) is described. It is essentially equipotent to indomethacin both in vitro and in vivo but without the ulcerogenic side effect due to COX-1 inhibition.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/9107377
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase 1, http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase 2, http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase 2 Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Indomethacin, http://linkedlifedata.com/resource/pubmed/chemical/Isoenzymes, http://linkedlifedata.com/resource/pubmed/chemical/Lactones, http://linkedlifedata.com/resource/pubmed/chemical/Membrane Proteins, http://linkedlifedata.com/resource/pubmed/chemical/PTGS1 protein, human, http://linkedlifedata.com/resource/pubmed/chemical/PTGS2 protein, human, http://linkedlifedata.com/resource/pubmed/chemical/Prostaglandin-Endoperoxide Synthases, http://linkedlifedata.com/resource/pubmed/chemical/Ptgs1 protein, rat, http://linkedlifedata.com/resource/pubmed/chemical/Sulfones, http://linkedlifedata.com/resource/pubmed/chemical/rofecoxib
pubmed:status	MEDLINE
pubmed:month	Jul
pubmed:issn	0960-894X
pubmed:author	pubmed-author:BrideauCC, pubmed-author:ChanC CCC, pubmed-author:CharlesonSS, pubmed-author:CromlishWW, pubmed-author:EthierDD, pubmed-author:EvansJ FJF, pubmed-author:Ford-HutchinsonA WAW, pubmed-author:GauthierJ YJY, pubmed-author:GordonRR, pubmed-author:GresserMM, pubmed-author:GubaAA, pubmed-author:KargmanSS, pubmed-author:KennedyBB, pubmed-author:LégerSS, pubmed-author:LeblancYY, pubmed-author:ManciniJJ, pubmed-author:O'NeillG PGP, pubmed-author:OuelletMM, pubmed-author:PercivalM DMD, pubmed-author:PerrierHH, pubmed-author:PrasitPP, pubmed-author:RiendeauDD, pubmed-author:RodgerII, pubmed-author:WangZZ, pubmed-author:ZamboniRR
pubmed:issnType	Print
pubmed:day	5
pubmed:volume	9
pubmed:owner	NLM
pubmed:authorsComplete	N
pubmed:pagination	1773-8
pubmed:dateRevised	2005-11-17
pubmed:meshHeading	pubmed-meshheading:10406640-Administration, Oral, pubmed-meshheading:10406640-Animals, pubmed-meshheading:10406640-Biological Availability, pubmed-meshheading:10406640-CHO Cells, pubmed-meshheading:10406640-Cricetinae, pubmed-meshheading:10406640-Cyclooxygenase 1, pubmed-meshheading:10406640-Cyclooxygenase 2, pubmed-meshheading:10406640-Cyclooxygenase 2 Inhibitors, pubmed-meshheading:10406640-Cyclooxygenase Inhibitors, pubmed-meshheading:10406640-Enzyme Inhibitors, pubmed-meshheading:10406640-Humans, pubmed-meshheading:10406640-Indomethacin, pubmed-meshheading:10406640-Inhibitory Concentration 50, pubmed-meshheading:10406640-Isoenzymes, pubmed-meshheading:10406640-Lactones, pubmed-meshheading:10406640-Membrane Proteins, pubmed-meshheading:10406640-Prostaglandin-Endoperoxide Synthases, pubmed-meshheading:10406640-Rats, pubmed-meshheading:10406640-Sulfones
pubmed:year	1999
pubmed:articleTitle	The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor.
pubmed:affiliation	Merck Frosst Centre for Therapeutic Research, Pointe Claire-Dorval, Québec, Canada.
pubmed:publicationType	Journal Article